Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1183/09031936.00011714 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.
J Clin Aesthet Dermatol
January 2025
Dr. Warren and Ms. Sanchez are with Derm Texas in Dallas, Texas.
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed.
View Article and Find Full Text PDFReal-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series.
J Clin Aesthet Dermatol
January 2025
Ms. Pomaville is with Forefront Dermatology in Berwyn, Illinois; the Marquette University College of Health Sciences, PA Studies Program in Milwaukee, Wisconsin; and the University of Dubuque, MSPAS Program, in Dubuque, Iowa.
Seborrheic dermatitis (SD) is an inflammatory skin disease with multifactorial etiology, involving genetic and environmental factors. Many conventional therapies for SD (ie, topical antifungals, topical corticosteroids) are associated with incomplete efficacy, frequent and sometimes rapid disease recurrence, and restrictions on duration of therapy and anatomic sites of application. This may be because they cannot target multiple disease processes and/or are limited by safety considerations.
View Article and Find Full Text PDFFirst-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL.
Cancers (Basel)
November 2024
Division of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is a serious type of cancer where the current treatment, R-CHOP, cures only about 60% of patients, prompting the need for improved therapies.
- Researchers investigated the combination of the FDA-approved PDE4 inhibitor roflumilast with R-CHOP in high-risk, treatment-naïve DLBCL patients, which showed safety and encouraging outcomes, with 70% of patients alive and disease-free at 44 months.
- Initial results indicate that roflumilast could enhance cancer treatment by inhibiting certain cancer-related signals and may be especially effective for specific high-risk genetic subtypes of DLBCL, suggesting further testing is needed.
The integrated effect of roflumilast and selenium nanoparticles on nephrotoxicity generated by cisplatin through the regulation of the antioxidant and apoptotic pathways.
J Trace Elem Med Biol
December 2024
Biochemistry Division, Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt.
Aim: The current investigations aimed to investigate the potential synergistic effect of Roflumilast (ROF) and Selenium nanoparticles (SeNPs) administration on Cisplatin (Cis) -induced nephrotoxicity.
Materials And Methods: Fifty male rats were divided into five groups; Control group: animals were administered 0.9 % saline solution.
Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study.
Int J Dermatol
December 2024
Oral Medicine Department, University of Valencia, Valencia, Spain.
Article Synopsis
- Severe recurrent aphthous stomatitis (RAS) significantly affects quality of life, and currently, no approved systemic treatments exist, prompting the exploration of roflumilast, a phosphodiesterase-4 inhibitor.
- In a study involving 22 RAS patients across five Spanish centers, roflumilast treatment resulted in substantial improvements, including an 88% reduction in flare-ups and a 94% decrease in oral ulcers over 12 weeks.
- Despite some adverse effects (mainly headache and gastrointestinal issues), roflumilast was generally well tolerated, showing promise as an effective and safe treatment option for RAS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!